Trial Profile
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; Carcinoma; Gastric cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Uterine cancer
- Focus Pharmacodynamics
- 01 Mar 2024 Results assessing assess tumoral PD response to talazoparib treatment published in the Cancer Chemotherapy and Pharmacology
- 27 Mar 2020 Status changed from recruiting to completed.
- 08 May 2019 Planned End Date changed from 6 Aug 2019 to 6 Aug 2020.